03:26 AM EDT, 08/19/2026 (MT Newswires) -- Scancell Holdings (SCLP.L) said Wednesday the UK Medicines and Healthcare Products Regulatory Agency granted a clinical trial authorization for a phase 3 registrational trial of its ImmunoBody iSCIB1+ in patients with advanced melanoma. The MHRA's clinical trial authorization follows the investigational new drug clearance from the US Food and Drug Administration, the clinical immuno-oncology company said Wednesday. The trial, which would enroll 550 patients with stage 3 or 4 unresectable melanoma, is expected to start by the end of 2026, with initial progression-free survival data expected in the second half of 2028.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.